Drug Profile

HBM 9027

Alternative Names: HBM-9027

Latest Information Update: 25 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dana-Farber Cancer Institute; Harbour BioMed
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

24 Jan 2024 US FDA approves IND application for HBM 9027 in Solid tumours
24 Jan 2024 Harbour BioMed plans a phase I trial in Solid tumours (Late-stage disease) in USA (Parenteral)
31 Aug 2022 Harbour BioMed announces intention to submit IND application for Cancer in 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com